Bioprosthetics Market Report 2026

Bioprosthetics Market Overview

• Bioprosthetics market size has reached to $6.27 billion in 2025 • Expected to grow to $9.77 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Rise In Cardiovascular Disorders Fueling The Growth Of Market Due To Increasing Need For Advanced Heart Valve And Vascular Replacements • Market Trend: Development Of Advanced Tissue Technologies Driving Innovation In Bioprosthetics • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Bioprosthetics Market?

Bioprosthetics is a branch of biomedical science that involves creating implants or devices from biological materials, sometimes combined with synthetic elements, to replace or support damaged or lost tissues in the body. These materials are engineered to resemble natural tissue in structure and function, ensuring compatibility with the body while reducing the risk of immune rejection and maintaining strength and long-term performance. The main types of bioprosthetics are allograft, xenograft, and autograft. An allograft refers to a tissue or organ transplant taken from a donor of the same species but genetically different from the recipient. Bioprosthetics are used in various applications, such as cardiovascular, orthopedic, wound healing, and others, by several end-users, including hospitals, specialty centers, and others.

What Is The Bioprosthetics Market Growth Forecast?

The bioprosthetics market size is expected to see strong growth in the next few years. It will grow to $9.77 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growth of personalized implants, advancements in tissue-engineered constructs, ai-driven prosthetic development, increasing adoption of smart prosthetic devices, expansion of orthopedic and reconstructive surgeries globally. Major trends in the forecast period include AI-enhanced prosthetic design, integration of biocompatible materials, personalized implant manufacturing, smart prosthetic devices with sensors, advanced tissue-engineered constructs.

Global Bioprosthetics Market Segmentation

1) By Type: Allograft, Xenograft, Autograft 2) By Application: Cardiovascular, Orthopedic, Wound healing, Other Applications 3) By End User: Hospitals, Specialty Centers, Other End Users Subsegments: 1) By Allograft: Cartilage Allograft, Tendon Allograft, Meniscus Allograft, Dental Allograft, Skin Allograft 2) By Xenograft: Porcine Heart Valve Xenograft, Bovine Heart Valve Xenograft, Porcine Dermis Xenograft, Bovine Pericardium Xenograft 3) By Autograft: Bone Autograft, Tendon Autograft, Skin Autograft, Cartilage Autograft

What Is The Driver Of The Bioprosthetics Market?

The rising cardiovascular diseases are expected to propel the growth of the bioprosthetics market going forward. Cardiovascular diseases refer to a group of disorders that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, arrhythmias, congenital heart defects, and cerebrovascular diseases such as stroke. The rising cardiovascular diseases are partly due to increasing consumption of unhealthy diets high in saturated fats, salt, and sugar, which contribute to obesity, hypertension, and high cholesterol levels. Bioprosthetics assist in treating cardiovascular diseases by replacing damaged heart valves or blood vessels with biologically compatible implants, enhancing heart performance and lowering the risk of complications. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the total number of cardiovascular-related deaths reached 931,578 in 2023, marking a slight increase from 928,741 deaths in 2022. Therefore, the rising cardiovascular diseases are driving the growth of the bioprosthetics industry.

Key Players In The Global Bioprosthetics Market

Major companies operating in the bioprosthetics market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Meril Life Sciences Pvt. Ltd., LivaNova PLC, Artivion Inc., LifeNet Health Inc., TTK Healthcare Limited, Corcym S.r.l., Biosensors International Group Ltd., Braile Biomedica, Xeltis NV, Peijia Medical Technology Co. Ltd., Labcor Laboratórios Ltda., Colibri Heart Valve LLC, Autotissue Berlin GmbH, Humacyte Inc., Bioprosthetics Inc., Shijiazhuang Perfect Prosthetic Manufacture Co. Ltd.

Global Bioprosthetics Market Trends and Insights

Major companies operating in the bioprosthetics market are focusing on developing advanced transcatheter heart valve (THV) technologies, such as non-metallic, leaflet-suspension designs, to boost procedural success, enhance patient outcomes, and reduce long-term complications. Non-metallic, leaflet-suspension designs refer to innovative valve architectures that use a polymer frame and a unique leaflet attachment method to optimize hemodynamics and durability. For instance, in December 2024, Meril Life Sciences, an India-based structural heart company, launched the Myval OCTAPRO THV series in Europe. It is a next-generation balloon-expandable transcatheter heart valve featuring a proprietary Octa-Armour polymer sleeve and an 8-point leaflet suspension design. This architecture is engineered to distribute stress more evenly, minimize leaflet fatigue, and improve coaptation, thereby aiming to enhance the valve's longevity and hemodynamic performance for patients with severe aortic stenosis.

What Are Latest Mergers And Acquisitions In The Bioprosthetics Market?

In July 2024, Edwards Lifesciences Corporation, a US-based medical technology company specializing in heart valves and critical care monitoring solutions, acquired Innovalve Bio Medical Ltd. for an undisclosed amount. Through this acquisition, Edwards Lifesciences aims to expand its structural heart portfolio and strengthen its transcatheter aortic valve replacement (TAVR) offerings globally. The deal is expected to accelerate product development, enhance clinical capabilities, and provide patients with broader access to minimally invasive heart valve therapies. Innovalve Bio Medical Ltd. is an Israel-based company specializing in bioprosthetics.

Regional Outlook

North America was the largest region in the bioprosthetics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Bioprosthetics Market?

The bioprosthetics market consists of revenues earned by entities by providing services such as custom implant design, biocompatibility testing, 3D modeling, and clinical research. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprosthetics market also includes sales of vascular grafts, cartilage repair scaffolds, bone grafts, dermal matrices, and biologic meshes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.